Clinical Trials Logo

Clinical Trial Summary

Both controlled ovarian stimulation (COS) and frozen embryo transfer has become an integral part of in vitro fertilization (IVF) treatment. Fresh embryo transfer is usually performed by providing Luteal Phase Support (LPS) with progesterone after COS. Frozen embryo transfer (FET) is usually performed in artificial cycles with hormone replacement treatment (HRT), in which exogenous progesterone is administered, although it can also be performed in a Natural Cycle (without hormone supplementation) (NC). There is evidence that the supraphysiologic levels of estradiol and progesterone during COS+LPS and HRT could lead to morphologic and biochemical endometrial modifications, altering endometrial receptivity and lowering implantation and pregnancy rates. We hypothesize that the supraphysiologic hormone levels required for both COS+LPS, and HRT may be inducing alterations in endometrial composition and function, specifically the chronic accumulation of senescent cells; either due to an excessive hormonal induction, a lack of clearance due to a deficit of uNKs, or a combination of both, ultimately affecting both endometrial receptivity and decidualization, worsening IVF outcomes. The in vitro clearance of endometrial senescent cells by selective induction of apoptosis has been found to enhance the decidualization capacity of the rest of Endometrial Stromal Cells (EnSC), which could represent in a future adjuvant strategy to reduce the potentially deleterious effects of supraphysiologic hormone levels and improve reproductive outcomes in IVF patients. The results derived from this project would have a direct impact on clinical practice. First, the results would allow us to evaluate, based on experimental data, potential endometrial side effects of stimulation protocols commonly used in IVF treatments. In addition, in the case of finding a pathological accumulation of senescent cells affecting endometrial receptivity, we will be able to in vitro evaluate the effectiveness of adjuvant senolytic (drugs designed to specifically remove senescent cells) compounds to in vitro improve the expression of endometrial receptivity markers, as a first step to demonstrate the effectiveness of their use in improving the reproductive outcomes of IVF patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06280560
Study type Observational [Patient Registry]
Source Fundación IVI
Contact Francisco Domínguez Hernández, PhD
Phone 963903305
Email francisco.dominguez@ivirma.com
Status Recruiting
Phase
Start date February 1, 2024
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04283435 - Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium Phase 1
Active, not recruiting NCT04286425 - Modification of Endometrial Receptivity After Vaginal Seminal Plasma Application N/A
Completed NCT01954758 - The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer N/A
Recruiting NCT04497558 - The Clinical Efficiency of Tb-ERA in Chinese RIF Patients N/A
Completed NCT03493529 - Microbiome and Endometrial Receptivity in Obese Infertile Women
Completed NCT03456375 - Serum and Uterine Progesterone Levels and ERA Test.
Active, not recruiting NCT03843034 - Endometrial Markers in Autoimmune Diseases
Recruiting NCT04499131 - Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters Phase 4
Completed NCT03887728 - Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles
Terminated NCT01606709 - Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation Phase 4